



# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

**Board Line :** +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/74

Date: 26<sup>th</sup> February, 2026

To,  
**The Listing Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828  
BSE Trading Symbol: SUDARSHAN  
ISIN: INE00TV01023

Sub: **Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Updates on GST Inspection, Search and Seizure**

Dear Sir / Madam,

In continuation to our earlier announcement dated February 22, 2026 and further developments thereto, we hereby inform you that a GST inspection or search operation was conducted by the Goods & Service Tax Department, Mumbai, Maharashtra, at the Registered Office of the Company. The said operation commenced on February 21, 2026 and concluded on February 25, 2026.


The officers of the Company fully co-operated with the officials of the GST Department throughout the operation and provided all necessary documents, information, and clarifications as requested.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 are given in Annexure-A.

We request you to kindly take the above information on record.

Thanking you,

For, **Sudarshan Pharma Industries Limited**

  
Hemal Mehta  
Chairman & Managing Director



Encl: As above



# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

**Board Line :** +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

## Annexure - A

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 are given below:

Sr. no.	Details to be provided	Detailed Information
1	Name of the Authority	Assistant Commissioner under the Maharashtra Goods & Service Tax Act 2017.
2	Nature and details of the action(s) taken, initiated or order(s) passed.	Search / Inspection under Section 67 of the Maharashtra Goods & Service Tax Act, 2017.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority.	The Search / Inspection commenced on Saturday, February 21, 2026 and concluded on Wednesday, February 25, 2026. No separate written direction and interim order received.
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed.	No violations or contraventions attributable to the compliance and filings at the end of Company were found.  Liability is on account of non-compliance by the vendor of the Company.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	There is no material impact on the Company's financials, operations or other activities.

For, Sudarshan Pharma Industries Limited

Hemal Mehta  
Chairman & Managing Director

